-transparent.png){kind=logo}
Six patients suffering from rheumatoid arthritis with massive knee joint effusions were treated with single daily doses of 600 mg pirazolac, a novel non-steroidal anti-inflammatory drug, for 3 days. Before the first dose, 3 hours after the second and the third dose, specimens of plasma and synovial fluid were drawn simultaneously. Plasma and synovial fluid concentrations of pirazolac, as determined by HPLC, amounted to 47.9 micrograms/ml and 19.8 micrograms/ml (Day 2) and 55.5 micrograms/ml and 18.7 micrograms/ml (Day 3), respectively. The samples were analyzed for PGE2, LTB4, LTC4 and LTD4 applying various extraction procedures and subsequent radioimmunoassays. PGE2 levels decreased during treatment from 928 pg/ml to 443 pg/ml after the third dose of pirazolac. LTB4 levels were slightly but insignificantly augmented. LTC4 and LTD4 concentrations were below the detection limit prior to and after administration of the drug.
M Kurowski, and
A Dunky, and
M Geddawi
November 1985,
Thrombosis research,
M Kurowski, and
A Dunky, and
M Geddawi
May 1990,
British journal of pharmacology,
M Kurowski, and
A Dunky, and
M Geddawi
January 2006,
Pharmacology,
M Kurowski, and
A Dunky, and
M Geddawi
October 1992,
Japanese journal of pharmacology,
M Kurowski, and
A Dunky, and
M Geddawi
January 1982,
Annals of the New York Academy of Sciences,
M Kurowski, and
A Dunky, and
M Geddawi
November 1985,
Seminars in arthritis and rheumatism,
M Kurowski, and
A Dunky, and
M Geddawi
February 2002,
Archives of dermatological research,
M Kurowski, and
A Dunky, and
M Geddawi
January 1985,
Agents and actions. Supplements,
M Kurowski, and
A Dunky, and
M Geddawi
February 1984,
Biochemical and biophysical research communications,
M Kurowski, and
A Dunky, and
M Geddawi
February 1980,
FEBS letters,
